{
  "api_version": "1",
  "request": {
    "url": "https://clinicaltrialsfind.com/api/v1/search.json?intervention=Cancer+Immunotherapy&page=2",
    "query": {
      "intervention": "Cancer Immunotherapy",
      "page": 2
    },
    "page_size": 10
  },
  "pagination": {
    "page": 2,
    "page_size": 10,
    "total_count": 1761,
    "total_pages": 177,
    "next_page_url": "https://clinicaltrialsfind.com/api/v1/search.json?intervention=Cancer+Immunotherapy&page=3&page_size=10",
    "previous_page_url": "https://clinicaltrialsfind.com/api/v1/search.json?intervention=Cancer+Immunotherapy&page=1&page_size=10"
  },
  "source": "remote",
  "last_synced_at": "2026-10-01T16:17:27.641Z",
  "attribution": "Data derived from public ClinicalTrials.gov records. The official record at https://clinicaltrials.gov/ remains the source of truth for current availability, contacts, and full study details.",
  "notes": [
    "This endpoint exposes only public summary fields — no participant contact emails, phone numbers, or scraped investigator contact details.",
    "For contact information and full protocol detail, follow each trial's `official_url` to the ClinicalTrials.gov record.",
    "This API is a navigational aid. It does not provide medical advice, eligibility determinations, or compensation guarantees."
  ],
  "trials": [
    {
      "nct_id": "NCT02224599",
      "title": "Cyclophosphamide, TAPA-Pulsed Dendritic Cell Therapy and Imiquimod in Progressive and/or Refractory Solid Malignancies",
      "overall_status": "TERMINATED",
      "study_type": "INTERVENTIONAL",
      "phases": [
        "PHASE1",
        "PHASE2"
      ],
      "conditions": [
        "Progressive Solid Malignancies",
        "Refractory Solid Malignancies",
        "Cancer"
      ],
      "interventions": [
        {
          "name": "TAPA-pulsed DC vaccine",
          "type": "BIOLOGICAL"
        },
        {
          "name": "Cyclophosphamide Pill",
          "type": "DRUG"
        },
        {
          "name": "Imiquimod Topical Cream",
          "type": "DRUG"
        }
      ],
      "intervention_types": [
        "BIOLOGICAL",
        "DRUG"
      ],
      "sponsor": "Kiromic BioPharma Inc.",
      "sponsor_class": "INDUSTRY",
      "healthy_volunteers": false,
      "eligibility": {
        "minimum_age": null,
        "maximum_age": null,
        "sex": "ALL",
        "summary": "Not listed"
      },
      "enrollment_count": 3,
      "start_date": "2017-07-28",
      "completion_date": "2018-08-30",
      "has_results": true,
      "last_update_posted_date": "2020-04-24",
      "last_synced_at": "2026-10-01T16:17:27.641Z",
      "location_count": 1,
      "location_summary": "San Antonio, Texas",
      "locations": [
        {
          "city": "San Antonio",
          "state": "Texas"
        }
      ],
      "official_url": "https://clinicaltrials.gov/study/NCT02224599"
    },
    {
      "nct_id": "NCT06875609",
      "title": "ctDNA in Cutaneous Squamous Cell Carcinoma",
      "overall_status": "RECRUITING",
      "study_type": "OBSERVATIONAL",
      "phases": [],
      "conditions": [
        "Cutaneous Squamous Cell Carcinoma"
      ],
      "interventions": [
        {
          "name": "Blood and Tissue Collection",
          "type": "DIAGNOSTIC_TEST"
        }
      ],
      "intervention_types": [
        "DIAGNOSTIC_TEST"
      ],
      "sponsor": "Massachusetts Eye and Ear Infirmary",
      "sponsor_class": "OTHER",
      "healthy_volunteers": false,
      "eligibility": {
        "minimum_age": "18 Years",
        "maximum_age": null,
        "sex": "ALL",
        "summary": "18 Years and older"
      },
      "enrollment_count": 60,
      "start_date": "2025-03-24",
      "completion_date": "2029-04-30",
      "has_results": false,
      "last_update_posted_date": "2026-03-30",
      "last_synced_at": "2026-10-01T16:17:27.641Z",
      "location_count": 1,
      "location_summary": "Boston, Massachusetts",
      "locations": [
        {
          "city": "Boston",
          "state": "Massachusetts"
        }
      ],
      "official_url": "https://clinicaltrials.gov/study/NCT06875609"
    },
    {
      "nct_id": "NCT03371992",
      "title": "Pilot Study of Nilogen 3D-EX and Its Ability to Predict Therapeutic Response to Anti-PD1 or Anti-PDL1 in NSCLC",
      "overall_status": "UNKNOWN",
      "study_type": "INTERVENTIONAL",
      "phases": [
        "EARLY_PHASE1"
      ],
      "conditions": [
        "Non Small Cell Lung Cancer"
      ],
      "interventions": [
        {
          "name": "Nivolumab",
          "type": "DRUG"
        },
        {
          "name": "3D-EX",
          "type": "DIAGNOSTIC_TEST"
        },
        {
          "name": "Evaluation of Response by RECIST",
          "type": "OTHER"
        }
      ],
      "intervention_types": [
        "DRUG",
        "DIAGNOSTIC_TEST",
        "OTHER"
      ],
      "sponsor": "Nilogen Oncosystems",
      "sponsor_class": "INDUSTRY",
      "healthy_volunteers": true,
      "eligibility": {
        "minimum_age": "18 Years",
        "maximum_age": null,
        "sex": "ALL",
        "summary": "18 Years and older"
      },
      "enrollment_count": 25,
      "start_date": "2018-03-09",
      "completion_date": "2021-06",
      "has_results": false,
      "last_update_posted_date": "2020-03-27",
      "last_synced_at": "2026-10-01T16:17:27.641Z",
      "location_count": 1,
      "location_summary": "Detroit, Michigan",
      "locations": [
        {
          "city": "Detroit",
          "state": "Michigan"
        }
      ],
      "official_url": "https://clinicaltrials.gov/study/NCT03371992"
    },
    {
      "nct_id": "NCT00070629",
      "title": "CPG 7909 Injection in Non-Small Cell Lung Cancer",
      "overall_status": "COMPLETED",
      "study_type": "INTERVENTIONAL",
      "phases": [
        "PHASE2"
      ],
      "conditions": [
        "Carcinoma, Non-Small Cell Lung"
      ],
      "interventions": [
        {
          "name": "CPG 7909",
          "type": "DRUG"
        },
        {
          "name": "Chemotherapy",
          "type": "DRUG"
        }
      ],
      "intervention_types": [
        "DRUG"
      ],
      "sponsor": "Pfizer",
      "sponsor_class": "INDUSTRY",
      "healthy_volunteers": false,
      "eligibility": {
        "minimum_age": "18 Years",
        "maximum_age": null,
        "sex": "ALL",
        "summary": "18 Years and older"
      },
      "enrollment_count": 116,
      "start_date": "2003-05",
      "completion_date": "2007-07",
      "has_results": false,
      "last_update_posted_date": "2009-02-10",
      "last_synced_at": "2026-10-01T16:17:27.641Z",
      "location_count": 17,
      "location_summary": "Gilroy, California • Los Angeles, California • Palm Springs, California + 14 more",
      "locations": [
        {
          "city": "Gilroy",
          "state": "California"
        },
        {
          "city": "Los Angeles",
          "state": "California"
        },
        {
          "city": "Palm Springs",
          "state": "California"
        },
        {
          "city": "Fort Myers",
          "state": "Florida"
        },
        {
          "city": "Indianapolis",
          "state": "Indiana"
        }
      ],
      "official_url": "https://clinicaltrials.gov/study/NCT00070629"
    },
    {
      "nct_id": "NCT01338012",
      "title": "Sipuleucel-T in Metastatic Castrate Resistant Prostate Cancer",
      "overall_status": "TERMINATED",
      "study_type": "INTERVENTIONAL",
      "phases": [
        "PHASE2"
      ],
      "conditions": [
        "Prostate Cancer"
      ],
      "interventions": [
        {
          "name": "sipuleucel-T",
          "type": "BIOLOGICAL"
        }
      ],
      "intervention_types": [
        "BIOLOGICAL"
      ],
      "sponsor": "Dendreon",
      "sponsor_class": "INDUSTRY",
      "healthy_volunteers": false,
      "eligibility": {
        "minimum_age": "18 Years",
        "maximum_age": null,
        "sex": "MALE",
        "summary": "18 Years and older · Male only"
      },
      "enrollment_count": 8,
      "start_date": "2011-12",
      "completion_date": "2015-04",
      "has_results": true,
      "last_update_posted_date": "2017-06-05",
      "last_synced_at": "2026-10-01T16:17:27.641Z",
      "location_count": 4,
      "location_summary": "Laguna Hills, California • Portland, Oregon • Seattle, Washington",
      "locations": [
        {
          "city": "Laguna Hills",
          "state": "California"
        },
        {
          "city": "Portland",
          "state": "Oregon"
        },
        {
          "city": "Seattle",
          "state": "Washington"
        },
        {
          "city": "Seattle",
          "state": "Washington"
        }
      ],
      "official_url": "https://clinicaltrials.gov/study/NCT01338012"
    },
    {
      "nct_id": "NCT07770100",
      "title": "Concurrent Immunotherapy and Systemic Therapy With Stereotactic Body Radiation Therapy (SBRT) for Stage IV Cancers (COINSSS IV)",
      "overall_status": "NOT_YET_RECRUITING",
      "study_type": "INTERVENTIONAL",
      "phases": [
        "PHASE2"
      ],
      "conditions": [
        "Head and Neck Cancer",
        "Non-Small Cell Lung Cancer",
        "Cervical Cancer",
        "Esophageal Cancer",
        "Gastric Cancer (GC)"
      ],
      "interventions": [
        {
          "name": "Stereotactic Body Radiation Therapy (SBRT)",
          "type": "RADIATION"
        },
        {
          "name": "Pembrolizumab",
          "type": "DRUG"
        },
        {
          "name": "Nivolumab",
          "type": "DRUG"
        },
        {
          "name": "Atezolizumab",
          "type": "DRUG"
        },
        {
          "name": "Ipilimumab",
          "type": "DRUG"
        }
      ],
      "intervention_types": [
        "RADIATION",
        "DRUG"
      ],
      "sponsor": "Mark Bernard",
      "sponsor_class": "OTHER",
      "healthy_volunteers": false,
      "eligibility": {
        "minimum_age": "18 Years",
        "maximum_age": "99 Years",
        "sex": "ALL",
        "summary": "18 Years to 99 Years"
      },
      "enrollment_count": 35,
      "start_date": "2026-10-01",
      "completion_date": "2040-02-28",
      "has_results": false,
      "last_update_posted_date": "2026-08-20",
      "last_synced_at": "2026-10-01T16:17:27.641Z",
      "location_count": 1,
      "location_summary": "Lexington, Kentucky",
      "locations": [
        {
          "city": "Lexington",
          "state": "Kentucky"
        }
      ],
      "official_url": "https://clinicaltrials.gov/study/NCT07770100"
    },
    {
      "nct_id": "NCT00081848",
      "title": "Vaccine Therapy and Radiation to Liver Metastasis in Patients With CEA-Positive Solid Tumors",
      "overall_status": "COMPLETED",
      "study_type": "INTERVENTIONAL",
      "phases": [
        "PHASE1"
      ],
      "conditions": [
        "Liver Neoplasms"
      ],
      "interventions": [
        {
          "name": "rV-CEA(6D)/TRICOM-rF-CEA(6D)/TRICOM",
          "type": "DRUG"
        },
        {
          "name": "rF-CEA(6D)/TRICOM",
          "type": "DRUG"
        },
        {
          "name": "Recombinant Fowlpox-GM-CSF",
          "type": "DRUG"
        },
        {
          "name": "Celecoxib",
          "type": "DRUG"
        }
      ],
      "intervention_types": [
        "DRUG"
      ],
      "sponsor": "National Cancer Institute (NCI)",
      "sponsor_class": "NIH",
      "healthy_volunteers": false,
      "eligibility": {
        "minimum_age": "18 Years",
        "maximum_age": null,
        "sex": "ALL",
        "summary": "18 Years and older"
      },
      "enrollment_count": 12,
      "start_date": "2004-04-20",
      "completion_date": "2007-08-23",
      "has_results": false,
      "last_update_posted_date": "2017-07-02",
      "last_synced_at": "2026-10-01T16:17:27.641Z",
      "location_count": 1,
      "location_summary": "Bethesda, Maryland",
      "locations": [
        {
          "city": "Bethesda",
          "state": "Maryland"
        }
      ],
      "official_url": "https://clinicaltrials.gov/study/NCT00081848"
    },
    {
      "nct_id": "NCT03866382",
      "title": "Testing the Effectiveness of Two Immunotherapy Drugs (Nivolumab and Ipilimumab) With One Anti-cancer Targeted Drug (Cabozantinib) for Rare Genitourinary Tumors",
      "overall_status": "RECRUITING",
      "study_type": "INTERVENTIONAL",
      "phases": [
        "PHASE2"
      ],
      "conditions": [
        "Bladder Adenocarcinoma",
        "Bladder Clear Cell Adenocarcinoma",
        "Bladder Mixed Adenocarcinoma",
        "Bladder Neuroendocrine Carcinoma",
        "Bladder Small Cell Neuroendocrine Carcinoma",
        "Bladder Squamous Cell Carcinoma",
        "Chromophobe Renal Cell Carcinoma",
        "Collecting Duct Carcinoma",
        "Invasive Bladder Giant Cell Urothelial Carcinoma",
        "Invasive Bladder Lymphoepithelioma-Like Carcinoma",
        "Invasive Bladder Nested Urothelial Carcinoma",
        "Invasive Bladder Plasmacytoid Urothelial Carcinoma",
        "Invasive Bladder Sarcomatoid Urothelial Carcinoma",
        "Invasive Bladder Urothelial Carcinoma",
        "Kidney Medullary Carcinoma",
        "Large Cell Neuroendocrine Carcinoma",
        "Malignant Testicular Leydig Cell Tumor",
        "Malignant Testicular Sertoli Cell Tumor",
        "Metastatic Bladder Carcinoma",
        "Metastatic Bladder Clear Cell (Glycogen-Rich) Urothelial Carcinoma",
        "Metastatic Bladder Giant Cell Urothelial Carcinoma",
        "Metastatic Bladder Large Cell Neuroendocrine Carcinoma",
        "Metastatic Bladder Lipid-Rich Urothelial Carcinoma",
        "Metastatic Bladder Micropapillary Urothelial Carcinoma",
        "Metastatic Bladder Plasmacytoid Urothelial Carcinoma",
        "Metastatic Bladder Sarcomatoid Urothelial Carcinoma",
        "Metastatic Bladder Small Cell Neuroendocrine Carcinoma",
        "Metastatic Bladder Squamous Cell Carcinoma",
        "Metastatic Chromophobe Renal Cell Carcinoma",
        "Metastatic Kidney Medullary Carcinoma",
        "Metastatic Malignant Genitourinary System Neoplasm",
        "Metastatic Papillary Renal Cell Carcinoma",
        "Metastatic Penile Carcinoma",
        "Metastatic Prostate Small Cell Neuroendocrine Carcinoma",
        "Metastatic Sarcomatoid Renal Cell Carcinoma",
        "Metastatic Urethral Carcinoma",
        "Papillary Renal Cell Carcinoma",
        "Sarcomatoid Renal Cell Carcinoma",
        "Stage IV Bladder Cancer AJCC v8",
        "Stage IV Penile Cancer AJCC v8",
        "Stage IV Renal Cell Cancer AJCC v8",
        "Stage IV Urethral Cancer AJCC v8",
        "Stage IVB Prostate Cancer AJCC v8",
        "Urachal Adenocarcinoma",
        "Urethral Clear Cell Adenocarcinoma"
      ],
      "interventions": [
        {
          "name": "Biospecimen Collection",
          "type": "PROCEDURE"
        },
        {
          "name": "Bone Scan",
          "type": "PROCEDURE"
        },
        {
          "name": "Cabozantinib S-malate",
          "type": "DRUG"
        },
        {
          "name": "Computed Tomography",
          "type": "PROCEDURE"
        },
        {
          "name": "Echocardiography Test",
          "type": "PROCEDURE"
        },
        {
          "name": "Ipilimumab",
          "type": "BIOLOGICAL"
        },
        {
          "name": "Magnetic Resonance Imaging",
          "type": "PROCEDURE"
        },
        {
          "name": "Nivolumab",
          "type": "BIOLOGICAL"
        },
        {
          "name": "Positron Emission Tomography",
          "type": "PROCEDURE"
        }
      ],
      "intervention_types": [
        "PROCEDURE",
        "DRUG",
        "BIOLOGICAL"
      ],
      "sponsor": "National Cancer Institute (NCI)",
      "sponsor_class": "NIH",
      "healthy_volunteers": false,
      "eligibility": {
        "minimum_age": "18 Years",
        "maximum_age": null,
        "sex": "ALL",
        "summary": "18 Years and older"
      },
      "enrollment_count": 314,
      "start_date": "2019-05-13",
      "completion_date": "2027-02-28",
      "has_results": false,
      "last_update_posted_date": "2026-09-30",
      "last_synced_at": "2026-10-01T16:17:27.641Z",
      "location_count": 580,
      "location_summary": "Birmingham, Alabama • Anchorage, Alaska • Kingman, Arizona + 376 more",
      "locations": [
        {
          "city": "Birmingham",
          "state": "Alabama"
        },
        {
          "city": "Anchorage",
          "state": "Alaska"
        },
        {
          "city": "Anchorage",
          "state": "Alaska"
        },
        {
          "city": "Anchorage",
          "state": "Alaska"
        },
        {
          "city": "Anchorage",
          "state": "Alaska"
        }
      ],
      "official_url": "https://clinicaltrials.gov/study/NCT03866382"
    },
    {
      "nct_id": "NCT02757391",
      "title": "CD8+ T Cell Therapy and Pembrolizumab in Treating Patients With Metastatic Gastrointestinal Tumors",
      "overall_status": "TERMINATED",
      "study_type": "INTERVENTIONAL",
      "phases": [
        "PHASE1"
      ],
      "conditions": [
        "Colorectal Adenocarcinoma",
        "Metastatic Cholangiocarcinoma",
        "Metastatic Colorectal Carcinoma",
        "Metastatic Digestive System Carcinoma",
        "Metastatic Esophageal Carcinoma",
        "Metastatic Gastric Carcinoma",
        "Metastatic Pancreatic Adenocarcinoma",
        "Stage IV Colorectal Cancer AJCC v7",
        "Stage IV Esophageal Cancer AJCC v7",
        "Stage IV Gastric Cancer AJCC v7",
        "Stage IV Pancreatic Cancer AJCC v6 and v7",
        "Stage IVA Colorectal Cancer AJCC v7",
        "Stage IVB Colorectal Cancer AJCC v7"
      ],
      "interventions": [
        {
          "name": "Adoptive Immunotherapy",
          "type": "BIOLOGICAL"
        },
        {
          "name": "Aldesleukin",
          "type": "BIOLOGICAL"
        },
        {
          "name": "Cyclophosphamide",
          "type": "DRUG"
        },
        {
          "name": "Laboratory Biomarker Analysis",
          "type": "OTHER"
        },
        {
          "name": "Pembrolizumab",
          "type": "BIOLOGICAL"
        }
      ],
      "intervention_types": [
        "BIOLOGICAL",
        "DRUG",
        "OTHER"
      ],
      "sponsor": "M.D. Anderson Cancer Center",
      "sponsor_class": "OTHER",
      "healthy_volunteers": false,
      "eligibility": {
        "minimum_age": "18 Years",
        "maximum_age": null,
        "sex": "ALL",
        "summary": "18 Years and older"
      },
      "enrollment_count": 1,
      "start_date": "2019-08-09",
      "completion_date": "2020-10-02",
      "has_results": false,
      "last_update_posted_date": "2020-10-30",
      "last_synced_at": "2026-10-01T16:17:27.641Z",
      "location_count": 1,
      "location_summary": "Houston, Texas",
      "locations": [
        {
          "city": "Houston",
          "state": "Texas"
        }
      ],
      "official_url": "https://clinicaltrials.gov/study/NCT02757391"
    },
    {
      "nct_id": "NCT05341349",
      "title": "Stereotactic Radiosurgery and Immune Checkpoint Inhibitors With NovoTTF-200M for the Treatment of Melanoma Brain Metastases",
      "overall_status": "TERMINATED",
      "study_type": "INTERVENTIONAL",
      "phases": [
        "PHASE1"
      ],
      "conditions": [
        "Clinical Stage IV Cutaneous Melanoma AJCC v8",
        "Melanoma of Unknown Primary",
        "Metastatic Malignant Neoplasm in the Brain",
        "Metastatic Melanoma",
        "Metastatic Mucosal Melanoma",
        "Metastatic Ocular Melanoma",
        "Pathologic Stage IV Cutaneous Melanoma AJCC v8"
      ],
      "interventions": [
        {
          "name": "Ipilimumab",
          "type": "BIOLOGICAL"
        },
        {
          "name": "Nivolumab",
          "type": "BIOLOGICAL"
        },
        {
          "name": "Pembrolizumab",
          "type": "BIOLOGICAL"
        },
        {
          "name": "Stereotactic Radiosurgery",
          "type": "RADIATION"
        },
        {
          "name": "Tumor Treating Fields Therapy",
          "type": "PROCEDURE"
        }
      ],
      "intervention_types": [
        "BIOLOGICAL",
        "RADIATION",
        "PROCEDURE"
      ],
      "sponsor": "Emory University",
      "sponsor_class": "OTHER",
      "healthy_volunteers": false,
      "eligibility": {
        "minimum_age": "22 Years",
        "maximum_age": null,
        "sex": "ALL",
        "summary": "22 Years and older"
      },
      "enrollment_count": 1,
      "start_date": "2022-10-13",
      "completion_date": "2024-05-31",
      "has_results": false,
      "last_update_posted_date": "2026-04-23",
      "last_synced_at": "2026-10-01T16:17:27.641Z",
      "location_count": 1,
      "location_summary": "Atlanta, Georgia",
      "locations": [
        {
          "city": "Atlanta",
          "state": "Georgia"
        }
      ],
      "official_url": "https://clinicaltrials.gov/study/NCT05341349"
    }
  ]
}